At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has exclusively invited Professor Rebecca Dent, Deputy Chief Executive Officer (Clinical) at the National Cancer Centre Singapore, to provide an in-depth analysis of the TROPION-Breast02 study, the primary results of which were already announced at the ESMO Annual Congress. The discussion will explore the transformative impact of TROP2 ADC on the first-line treatment landscape for advanced triple-negative breast cancer.
